Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is an adaptive Phase IB-II trial of a vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF, to prevent COVID-19 in adults.
Description: Confirm safety of AV-COVID-19 by adverse event monitoring
Measure: Confirm safety Time: 6 monthsDescription: Measurement of IgG and IgM in subject blood
Measure: Suggestion of efficacy Time: 6 monthsDescription: Measurement of IgG and IgM in subject blood
Measure: Optimal dose of SARS-CoV-2 antigen Time: 6 monthsDescription: Measurement of IgG and IgM in subject blood
Measure: Advantage of administering vaccine admixed with GM-CSF Time: 6 monthsDescription: Measurement of IgG and IgM in subject blood
Measure: Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination Time: 6 months